Jefferies Financial Group Reaffirms “Buy” Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “buy” rating restated by investment analysts at Jefferies Financial Group in a report released on Tuesday, Digital Look reports. They presently have a GBX 2,500 price objective on the stock. Jefferies Financial Group’s target price points to a potential upside of 33.83% from the company’s current price.

Other research analysts also recently issued research reports about the stock. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 1,975 target price on shares of GSK in a research note on Tuesday, September 8th. Berenberg Bank increased their price target on shares of GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a report on Tuesday, September 15th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 2,000 price target on shares of GSK in a research report on Tuesday, September 29th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of GBX 2,064.38.

GSK Stock Down 0.0%

GSK stock traded down GBX 0.50 during mid-day trading on Tuesday, reaching GBX 1,868. The stock had a trading volume of 9,241,153 shares, compared to its average volume of 12,467,660. The company has a market capitalization of £74.85 billion, a price-to-earnings ratio of 15.86, a PEG ratio of 1.24 and a beta of 0.29. The company has a 50-day moving average price of GBX 1,845.32 and a two-hundred day moving average price of GBX 1,920.39. GSK has a one year low of GBX 1,592 and a one year high of GBX 2,282. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73.

GSK (LON:GSK) last announced its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. On average, analysts expect that GSK will post 175.98 EPS for the current fiscal year.

Insider Buying and Selling at GSK

In other GSK news, insider Jonathan Symonds acquired 1,500 shares of the company’s stock in a transaction that occurred on Friday, September 18th. The shares were bought at an average cost of GBX 1,881 per share, with a total value of £28,215. Also, insider Anne Beal acquired 637 shares of GSK stock in a transaction that occurred on Friday, September 18th. The stock was acquired at an average price of GBX 4,985 per share, with a total value of £31,754.45. Insiders have purchased 2,151 shares of company stock worth $6,021,921 over the last ninety days. 0.20% of the stock is currently owned by insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.